Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?

Cipla shares rose 4% after Citi placed the stock on a 90-day catalyst watch, citing near-term triggers including likely approval of gFlovent from the Goa facility, launch of gVentolin, and an upcoming re-inspection of the Indore plant. The brokerage noted that Nintedanib has captured nearly 50% US market share and that earnings have likely bottomed out after the gRevlimid-related decline, with the stock trading at 25x FY27E earnings. Despite the optimism, Cipla reported a 55% year-on-year drop in Q4 consolidated net profit to Rs 555 crore, with revenue down about 3% to Rs 6,541 crore, though the India business remains a key earnings driver.